Identification of biomarkers and potential therapeutic targets for pancreatic cancer by proteomic analysis in two prospective cohorts
- PMID: 38754433
- PMCID: PMC11228889
- DOI: 10.1016/j.xgen.2024.100561
Identification of biomarkers and potential therapeutic targets for pancreatic cancer by proteomic analysis in two prospective cohorts
Abstract
Pancreatic cancer (PC) is the deadliest malignancy due to late diagnosis. Aberrant alterations in the blood proteome might serve as biomarkers to facilitate early detection of PC. We designed a nested case-control study of incident PC based on a prospective cohort of 38,295 elderly Chinese participants with ∼5.7 years' follow-up. Forty matched case-control pairs passed the quality controls for the proximity extension assay of 1,463 serum proteins. With a lenient threshold of p < 0.005, we discovered regenerating family member 1A (REG1A), REG1B, tumor necrosis factor (TNF), and phospholipase A2 group IB (PLA2G1B) in association with incident PC, among which the two REG1 proteins were replicated using the UK Biobank Pharma Proteomics Project, with effect sizes increasing steadily as diagnosis time approaches the baseline. Mendelian randomization analysis further supported the potential causal effects of REG1 proteins on PC. Taken together, circulating REG1A and REG1B are promising biomarkers and potential therapeutic targets for the early detection and prevention of PC.
Keywords: Mendelian randomization; biomarker; circulating protein; incident pancreatic cancer; prospective study; risk stratification.
Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests The authors declare no competing interests.
Figures





Similar articles
-
Reg proteins promote acinar-to-ductal metaplasia and act as novel diagnostic and prognostic markers in pancreatic ductal adenocarcinoma.Oncotarget. 2016 Nov 22;7(47):77838-77853. doi: 10.18632/oncotarget.12834. Oncotarget. 2016. PMID: 27788482 Free PMC article.
-
Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9.BMC Cancer. 2013 Sep 3;13:404. doi: 10.1186/1471-2407-13-404. BMC Cancer. 2013. PMID: 24007603 Free PMC article.
-
Macrophage inhibitory cytokine-1/growth differentiation factor-15 in premalignant and neoplastic tumours in a high-risk pancreatic cancer cohort.World J Gastroenterol. 2020 Apr 14;26(14):1660-1673. doi: 10.3748/wjg.v26.i14.1660. World J Gastroenterol. 2020. PMID: 32327914 Free PMC article.
-
Proteomic profiling of pancreatic cancer for biomarker discovery.Mol Cell Proteomics. 2005 Apr;4(4):523-33. doi: 10.1074/mcp.R500004-MCP200. Epub 2005 Jan 31. Mol Cell Proteomics. 2005. PMID: 15684406 Review.
-
Analytically validated protein biomarkers of chronic pancreatitis and pancreatic cancer for potential clinical diagnosis with mass spectrometry.Rapid Commun Mass Spectrom. 2020 Apr;34 Suppl 1:e8580. doi: 10.1002/rcm.8580. Epub 2020 Feb 5. Rapid Commun Mass Spectrom. 2020. PMID: 31502717
Cited by
-
Proteomic Signatures as Biomarkers of Atherosclerosis Burden.Res Sq [Preprint]. 2025 Jun 10:rs.3.rs-6837440. doi: 10.21203/rs.3.rs-6837440/v1. Res Sq. 2025. PMID: 40585252 Free PMC article. Preprint.
-
Advancing Precision Medicine in PDAC: An Ethical Scoping Review and Call to Action for IHC Implementation.Cancers (Basel). 2025 Jun 6;17(12):1899. doi: 10.3390/cancers17121899. Cancers (Basel). 2025. PMID: 40563550 Free PMC article. Review.
-
The influence of metformin treatment on the circulating proteome.EBioMedicine. 2025 Aug;118:105859. doi: 10.1016/j.ebiom.2025.105859. Epub 2025 Jul 19. EBioMedicine. 2025. PMID: 40684475 Free PMC article.
References
-
- Siegel R.L., Giaquinto A.N., Jemal A. Cancer statistics, 2024. CA. Cancer J. Clin. 2024;74:12–49. - PubMed
-
- Mizrahi J.D., Surana R., Valle J.W., Shroff R.T. Pancreatic cancer. Lancet. 2020;395:2008–2020. - PubMed
-
- Suhre K., McCarthy M.I., Schwenk J.M. Genetics meets proteomics: perspectives for large population-based studies. Nat. Rev. Genet. 2021;22:19–37. - PubMed
-
- Winter J.M., Yeo C.J., Brody J.R. Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer. J. Surg. Oncol. 2013;107:15–22. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical